Last reviewed · How we verify

Botulinum Toxin Type A Injection [Xeomin]

Assistance Publique - Hôpitaux de Paris · Phase 3 active Small molecule

Botulinum Toxin Type A Injection [Xeomin] is a Neuromuscular blocking agent Small molecule drug developed by Assistance Publique - Hôpitaux de Paris. It is currently in Phase 3 development for Cervical dystonia, Blepharospasm, Hemifacial spasm. Also known as: Xeomin.

Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis. Used for Cervical dystonia, Blepharospasm, Hemifacial spasm.

At a glance

Generic nameBotulinum Toxin Type A Injection [Xeomin]
Also known asXeomin
SponsorAssistance Publique - Hôpitaux de Paris
Drug classNeuromuscular blocking agent
TargetSNAP-25 (synaptosome-associated protein of 25 kDa)
ModalitySmall molecule
Therapeutic areaNeurology; Aesthetics
PhasePhase 3

Mechanism of action

Xeomin is a purified botulinum toxin type A that irreversibly cleaves SNAP-25, a protein essential for acetylcholine vesicle fusion and release at the neuromuscular junction. This prevents muscle contraction in the injected area. The effect is temporary, lasting 3-4 months, after which nerve terminals regenerate and muscle function returns.

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Botulinum Toxin Type A Injection [Xeomin]

What is Botulinum Toxin Type A Injection [Xeomin]?

Botulinum Toxin Type A Injection [Xeomin] is a Neuromuscular blocking agent drug developed by Assistance Publique - Hôpitaux de Paris, indicated for Cervical dystonia, Blepharospasm, Hemifacial spasm.

How does Botulinum Toxin Type A Injection [Xeomin] work?

Botulinum toxin type A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

What is Botulinum Toxin Type A Injection [Xeomin] used for?

Botulinum Toxin Type A Injection [Xeomin] is indicated for Cervical dystonia, Blepharospasm, Hemifacial spasm, Glabellar lines (aesthetic indication), Chronic migraine.

Who makes Botulinum Toxin Type A Injection [Xeomin]?

Botulinum Toxin Type A Injection [Xeomin] is developed by Assistance Publique - Hôpitaux de Paris (see full Assistance Publique - Hôpitaux de Paris pipeline at /company/assistance-publique-h-pitaux-de-paris).

Is Botulinum Toxin Type A Injection [Xeomin] also known as anything else?

Botulinum Toxin Type A Injection [Xeomin] is also known as Xeomin.

What drug class is Botulinum Toxin Type A Injection [Xeomin] in?

Botulinum Toxin Type A Injection [Xeomin] belongs to the Neuromuscular blocking agent class. See all Neuromuscular blocking agent drugs at /class/neuromuscular-blocking-agent.

What development phase is Botulinum Toxin Type A Injection [Xeomin] in?

Botulinum Toxin Type A Injection [Xeomin] is in Phase 3.

What are the side effects of Botulinum Toxin Type A Injection [Xeomin]?

Common side effects of Botulinum Toxin Type A Injection [Xeomin] include Headache, Neck pain, Injection site pain, Muscle weakness, Eyelid ptosis, Dysphagia.

What does Botulinum Toxin Type A Injection [Xeomin] target?

Botulinum Toxin Type A Injection [Xeomin] targets SNAP-25 (synaptosome-associated protein of 25 kDa) and is a Neuromuscular blocking agent.

Related